1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Demographic, clinical, and MRI findings of the patients with MS and the NCs included in the study
NC (n = 28) cMS (n = 35) aMS (n = 57)
Age (years) 13.3 ± 2.8 (10–16) 13.2 ± 2.0 (8–16) 37.4 ± 7.2 (18–55)^a,^b
Age at onset (years) n.a. 12.5 ± 1.8 (7–15) 36.9 ± 6.9 (18–54)^b
Patients with BOIgG n.a 30 (85.7%) 51 (89.5%)
EDSS-baseline n.a. 1.4 ± 0.8 (0–3.0) 3.2 ± 1.5 (1.0–7.0)^b
T2WMLV (cm³) n.a. 4.0 ± 5.9 (0.2–27.5) 7.4 ± 9.4 (0.3–67.6)^b
Patients with CEL n.a. 7 (20.0%) 12 (21.1%)
Number of CEL n.a. 1.3 ± 0.4 (1–4) 1.1 ± 0.3 (1–3)
GMf-baseline % 53.9 ± 2.0(49.4–57.6) 53.0 ± 2.8(49.9–56.2) 49.9 ± 3.3(47.3–53.0)^a,^b
Patients with CLs n.a. 12 (34.3%) 35 (61.4%)^b
CL number n.a 2.1 ± 1.7 (1–12) 3.8 ± 2.6 (1–20)^b
CL volume (mm³) n.a 240 ± 89 (0–745) 451 ± 125 (0–1250)^b
Note:—Data are reported as mean ± standard deviation (range).
BOIgG indicates immunoglobin G oligoclonal bands; n.a., not applicable; CEL, contrast-enhancing lesion.

 
↵a P < 0.001 (compared with NC).

 
↵b P < 0.001 (compared with cMS).